Mereo BioPharma Group plc
MREO
$2.74
$0.2811.38%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -79.15% | -46.79% | -51.43% | -8.91% | 40.29% |
| Total Depreciation and Amortization | -2.34% | 2.54% | 13.85% | 24.23% | 25.41% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 39.47% | 9.41% | 437.59% | 345.68% | 549.71% |
| Change in Net Operating Assets | 117.95% | 76.84% | -97.32% | 155.64% | -20.42% |
| Cash from Operations | -66.90% | -55.38% | -10.13% | 54.50% | 58.66% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 57.29% | -66.83% | -5,823.73% | -258.86% | -166.14% |
| Cash from Investing | 54.43% | -66.83% | -5,582.93% | -259.41% | -166.63% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | 100.00% | -717.83% | -1,186.20% |
| Issuance of Common Stock | 309.19% | 305.00% | 305.00% | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -106.76% | -92.12% | -86.38% | -914.73% | -548.03% |
| Cash from Financing | 484.08% | 478.79% | 459.92% | 8,930.22% | 2,145.28% |
| Foreign Exchange rate Adjustments | -48.80% | -108.27% | 151.10% | 104.68% | 112.74% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 224.00% | 215.05% | 173.47% | 164.18% | 80.81% |